Markets Breathe Sigh of Relief After Mylan’s Perrigo Bid Fails

Mylan shares soar after it failed to win backing from more than 40% of Perrigo shareholders.

comments Print
The $66 billion m nage a trois between Teva Pharmaceuticals, Mylan and Perrigo came to end on Friday with none of the companies pairing off with any of the others.